This license will enable Oxford Nanopore to enhance its DNA/RNA sequencing platform. “GR’s novel negative enrichment approach has exciting potential synergy with Oxford Nanopore’s platform,” commented Dr. Gordon Sanghera, CEO of Oxford Nanopore.

The new approach to targeting long DNA fragments for sequence-specific enrichment will allow users of Oxford Nanopore technology to focus on specific genomic regions that are of interest in a multiplex manner. This will allow Oxford Nanopore to bring rapid, near-sample targeted sequencing to market.

GR’s CRISPR-based enrichment platform provides next-generation targeted enrichment complementary to polymerase chain reaction and hybrid capture that can be applied to both long and short DNA fragments.

The terms of the nonexclusive license agreement were not disclosed.

Related Reading

Copyright © 2020


READ  Facebook tells users the source and date of coronavirus stories before they share them


Please enter your comment!
Please enter your name here